

## United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
08/486,069	06/07/1995	DEAN ENGELHARDT	ENZ-5(D8)(C2	6278
28171	7590 11/21/2005		EXAMINER	
ENZO BIOCHEM, INC. 527 MADISON AVENUE (9TH FLOOR)			BRUSCA, JOHN S	
NEW YORK	•	(OOR)	ART UNIT	PAPER NUMBER
			1631	,

DATE MAILED: 11/21/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

· · · · · ·	Application No.	Applicant(s)		
Examiner-Initiated Interview Summary	08/486,069	ENGELHARDT ET AL.		
Examiner-initiated interview Summary	Examiner	Art Unit		
	John S. Brusca	1631		
All Participants:	Status of Application: <u>140</u>			
(1) John S. Brusca.	(3)			
(2) <u>Ron Fedus</u> .	(4)			
Date of Interview:	Time:			
Type of Interview:  ☐ Telephonic ☐ Video Conference ☐ Personal (Copy given to: ☐ Applicant ☐ Applicant  Exhibit Shown or Demonstrated: ☐ Yes ☐ No If Yes, provide a brief description:	ant's representative)			
Part I.				
Rejection(s) discussed:				
Claims discussed: 1703, 1784				
Prior art documents discussed:				
Part II.				
SUBSTANCE OF INTERVIEW DESCRIBING THE GENE See Continuation Sheet	RAL NATURE OF WHAT WAS	S DISCUSSED:		
Part III.				
<ul> <li>It is not necessary for applicant to provide a separate directly resulted in the allowance of the application. The of the interview in the Notice of Allowability.</li> <li>It is not necessary for applicant to provide a separate did not result in resolution of all issues. A brief summar</li> </ul>	e examiner will provide a writtorecord of the	en summary of the substance interview, since the interview		
		·		
Jel Burea 4 November 2005				
(Examiner/SPE Signature) (Applicant/Applicant's Representative Signature – if appropriate)				

Continuation of Substance of Interview including description of the general nature of what was discussed: The applicants were requested to determine the most recent amendment to the claim for priority, and the most recent amendment to the abstract. The applicants stated they would respond with the paper dates of the most recent claim for priority and abstract amendment. The applicants were requested to correct antecedent basis for "said metal or metal ion" in claim 1703, and to point to written description support for claim 1784 drawn to a nuclease assay. The applicants were informed that no rejections for double patenting were contemplated in the instant application.